How does CHGX's PB Ratio compare to its peers?

CHGX has negative equity and a Price-To-Book Ratio (-0.1x) compared to the peer average (16.7x).

How does CHGX's PB Ratio compare vs other companies in the CA Biotechs Industry?

CHGX has negative equity and a Price-To-Book Ratio (-0.1x) compared to the Canadian Biotechs industry average (2.6x).

What is CHGX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate CHGX's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of CHGX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate CHGX's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

ChitogenX (CNSX:CHGX) - Stock Price, News & Analysis

CHGX Stock Overview

An orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of orthopaedic and sports medicine surgeries in Canada. More details

CHGX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Earnings have declined by 1.4% per year over past 5 years

Negative shareholders equity

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (CA$0)

+ 2 more risks

ChitogenX Inc. Competitors

GeneTether Therapeutics

CNSX:GTTX

CA$3.9m

Entheon Biomedical

CNSX:ENBI

CA$1.2m

Vaxil Bio

TSXV:VXL

CA$1.4m

NAVCO Pharmaceuticals

TSXV:NAV

CA$1.1m

Price History & Performance

Summary of all time highs, changes and price drops for ChitogenX
Historical stock prices
Current Share Price	CA$0.005
52 Week High	CA$0.12
52 Week Low	CA$0.005
Beta	-0.074
11 Month Change	-50.00%
3 Month Change	-83.33%
1 Year Change	-95.24%
33 Year Change	-98.68%
5 Year Change	-97.22%
Change since IPO	-99.50%

Recent updates

Shareholder Returns

	CHGX	CA Biotechs	CA Market
7D	-50.0%	-8.9%	1.3%
1Y	-95.2%	-1.9%	23.1%

Return vs Industry: CHGX underperformed the Canadian Biotechs industry which returned 1.5% over the past year.

Return vs Market: CHGX underperformed the Canadian Market which returned 21.7% over the past year.

Price Volatility

Is CHGX's price volatile compared to industry and market?
CHGX volatility
CHGX Average Weekly Movement	92.4%
Biotechs Industry Average Movement	11.7%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.8%
10% least volatile stocks in CA Market	2.9%

Stable Share Price: CHGX's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: Insufficient data to determine CHGX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2015	n/a	Pierre Laurin	www.chitogenx.com

ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of orthopaedic and sports medicine surgeries in Canada. It develops Ortho-R, a biopolymer for rotator cuff repair; and Ortho-M, a biopolymer for meniscus repair. The company was formerly known as Ortho Regenerative Technologies Inc. and changed its name to ChitogenX Inc. in September 2022.

ChitogenX Inc. Fundamentals Summary

How do ChitogenX's earnings and revenue compare to its market cap?
CHGX fundamental statistics
Market cap	CA$415.65k
Earnings (TTM)	-CA$1.73m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Is CHGX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CHGX income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$1.73m
Earnings	-CA$1.73m

Last Reported Earnings

Jul 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.021
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-60.9%

How did CHGX perform over the long term?

See historical performance and comparison

CHGX Stock Overview

Risk Analysis

ChitogenX Inc. Competitors

CNSX:GTTX

CA$3.9m

CNSX:ENBI

CA$1.2m

TSXV:VXL

CA$1.4m

TSXV:NAV

CA$1.1m

Price History & Performance

Recent News & Updates

Insufficient new directors

New major risk - Revenue and earnings growth

Chitogenx Inc. Demonstrates ORTHO-R Efficacy and Osteoarthritidevelopment in Large Animal Study

New major risk - Financial position

Chitogenx Concludes Enrolment for Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial

Less than half of directors are independent

Recent updates

Insufficient new directors

New major risk - Revenue and earnings growth

Chitogenx Inc. Demonstrates ORTHO-R Efficacy and Osteoarthritidevelopment in Large Animal Study

New major risk - Financial position

Chitogenx Concludes Enrolment for Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial

Less than half of directors are independent

New major risk - Share price stability

ChitogenX Inc., Annual General Meeting, Jul 19, 2023

ChitogenX Inc. announced that it has received CAD 3.856348 million in funding

ChitogenX Inc. Demonstrates Ortho-R Residency Properties in Meniscus Study

ChitogenX Inc. announced that it expects to receive CAD 6.1 million in funding

Chitogenx Successfully Completes Initial Portion of Its U.S. Phase I/Ii Rotator Cuff Repair Clinical Trial

ChitogenX Inc. Launches Second Orthopedic Development Program in Meniscus Repair

High number of new directors

Ortho Regenerative Technologies Inc. Announces Enrollment of First Patient in Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial

Ortho Regenerative Technologies Inc. Initiates Patients Recruitment for its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial

Ortho Regenerative Technologies Receives Key U.S. Composition and Method Patent for Ortho-R Soft Tissue Repair Platform

High number of new directors

Ortho Regenerative Technologies Inc. announced that it has received CAD 3.2 million in funding

Ortho Regenerative Technologies Inc. announced that it expects to receive CAD 3 million in funding

Ortho Regenerative Technologies Inc. Announces U.S. IND Clinical Hold Lifted by the FDA & Clearance to Proceed with U.S. Clinical Trial

Ortho Regenerative Technologies Announces Extension of FDA Clinical Hold of ORTHO-R Investigational New Drug Application

Ortho Regenerative Technologies Inc. Receives Clinical Hold Letter from the U.S. Food and Drug Administration

Forecast to breakeven in 2026

New 90-day low: CA$0.54

President exercised options to buy CA$106k worth of stock.

Ortho Regenerative Technologies Inc. Announces Board Changes

Ortho Regenerative Technologies Inc. Enters into Global Licensing Agreement with Hanuman Pelican Inc

Ortho Regenerative Technologies Inc. announced that it has received CAD 3 million in funding from Leede Jones Gable Inc.

New 90-day high: CA$0.74

Ortho Regenerative Technologies Inc. Announces Appointment of Mukesh Ahuja as Vice-President Clinical and Medical Affairs, Effective November 1, 2020

Ortho Regenerative Technologies Inc. announced that it has received CAD 0.1376 million in funding

Ortho Regenerative Technologies Inc. announced that it expects to receive CAD 0.2 million in funding

New 90-day high - CA$0.43

Ortho Regenerative Technologies Inc. announced that it has received CAD 2.47482 million in funding

Ortho Regenerative Technologies Inc. announced that it expects to receive CAD 0.64 million in funding